Evidence map›Paper›PMID 27106057›Full record

ArticleNucleic acids research2016

USR-VS: a web server for large-scale prospective virtual screening using ultrafast shape recognition techniques.

Hongjian Li, Kwong-S Leung, Man-H Wong, Pedro J Ballester

Abstract read
In one paragraph

Article in Nucleic acids research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Development and Testing of Druglike Screening Libraries.Journal of chemical information and modeling · 2019
    Article
  8. Current computational methods for predicting protein interactions of natural products.Computational and structural biotechnology journal · 2019
    Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hongjian LiInstitute of Future Cities, Chinese University of Hong Kong, Hong Kong.
Kwong-S LeungDepartment of Computer Science and Engineering, Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong.
Man-H WongDepartment of Computer Science and Engineering, Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong.
Pedro J BallesterCancer Research Center of Marseille, INSERM U1068, 13009-Marseille, France pedro.ballester@inserm.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ligand-based Virtual Screening (VS) methods aim at identifying molecules with a similar activity profile across phenotypic and macromolecular targets to that of a query molecule used as search template. VS using 3D similarity methods have the advantage of biasing this search toward active molecules with innovative chemical scaffolds, which are highly sought after in drug design to provide novel leads with improved properties over the query molecule (e.g. patentable, of lower toxicity or increased potency). Ultrafast Shape Recognition (USR) has demonstrated excellent performance in the discovery of molecules with previously-unknown phenotypic or target activity, with retrospective studies suggesting that its pharmacophoric extension (USRCAT) should obtain even better hit rates once it is used prospectively. Here we present USR-VS (http://usr.marseille.inserm.fr/), the first web server using these two validated ligand-based 3D methods for large-scale prospective VS. In about 2 s, 93.9 million 3D conformers, expanded from 23.1 million purchasable molecules, are screened and the 100 most similar molecules among them in terms of 3D shape and pharmacophoric properties are shown. USR-VS functionality also provides interactive visualization of the similarity of the query molecule against the hit molecules as well as vendor information to purchase selected hits in order to be experimentally tested.

Indexed as

InternetSoftwareDrug DesignDrug Evaluation, PreclinicalFluspirileneIndolesLigandsPharmaceutical PreparationsReproducibility of ResultsSulfonamidesVemurafenibFluspirileneIndolesLigandsPharmaceutical PreparationsSulfonamidesVemurafenib

Identifiers

PMID27106057
PMCPMC4987897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.